Filter By:
Medical Devices
ALung Technologies
ALung Technologies respiratory assist system, called Hemolung (RAS), is for patients with acute exacerbations of chronic obstructive pulmonary disease, a $6.3B world-wide market.
Current Stage: Growth
BioSafe
BIOSAFE’s proven polymer technology offers long lasting antimicrobial protection against bacteria, viruses, molds and algae, without promoting the emergence of drug resistant microbes. BIOSAFE was acquired by Gelest in April 2016.
Current Stage: Exited
Blue Belt Technologies
Blue Belt Technologies’ proprietary and differentiated handheld robotic technology, Navio® Surgical System, helps surgeons deliver precise and consistent results for their patients. Blue Belt Technologies was acquired by Smith & Nephew in October 2015 for a total of $275 million.
Current Stage: Exited
Carmell Therapeutics
Carmell Therapeutics has developed a proprietary technology that enables the manufacture of biologically-active materials from human blood plasma. These plasma-based materials contain a concentration of natural regenerative factors that promote healing, reduce complications, and save healthcare costs. The company is currently conducting clinical trials in the orthopedic and surgical site infection markets.
Current Stage: Early
ChemDAQ
ChemDAQ designs and markets toxic (sterilant) gas monitoring systems that help protect workers from exposure to airborne toxins, ensuring employee safety and meeting federal regulatory requirements.
Current Stage: Growth
Circadiance
Circadiance manufactures and markets innovative solutions for the 12 Million Obstructive Sleep Apnea (OSA) patients, including innovative soft mask products designed to improve the patient compliance rate, only 45%.
Current Stage: Growth
ClearCount
ClearCount developed revolutionary products to replace the antiquated method of manually counting surgical sponges post-surgery with a closed-loop sponge count reconciliation and detection solution, and a radiofrequency identification-detection solution. ClearCount was acquired by Stryker Medical in 2014.
Current Stage: Exited
Forest Devices
Forest Devices has created a proprietary product that enables EMTs to quickly detect stroke so they can route patients directly to stroke treatment centers, thus eliminating the delay in treatment which leads to worse health outcomes, disabilities, and over $50B in healthcare costs in the U.S.
Current Stage: Seed
Intelomed
Intelomed has developed a non-invasive device that dynamically assesses a patient’s cardiovascular health by analyzing pulse and pulse oximetry waveforms in response to small perturbations. The company has received FDA and European (CE Mark) approvals for their first product, CVInsight® Patient Monitoring & Informatics System.
Current Stage: Growth
Medrobotics
Medrobotics has developed a unique, flexible, minimally invasive robotic platform, Flex® Robotic System, enabling surgeons to access difficult to reach anatomy, via a single-port, and perform advanced surgeries.
Current Stage: Growth
Neuro Kinetics
Neuro Kinetics, Inc. (NKI) has developed a unique, eye tracking technology to be used for non-invasive, neuro-otologic diagnostic testing. The company’s I-Portal® system measures eye movements generated by the brain in response to specific test stimuli providing a non-invasive, multimodal diagnostic tool. The company is expanding its applications to include concussions and is currently conducting clinical trials.
Current Stage: Growth
PECA Labs
A CMU and University of Pittsburgh spin-off with a focus in pediatric and cardiovascular surgical device space, PECA labs has developed a synthetic valve conduit for pediatric right ventricular outflow tract (RVOT) reconstruction and a valve shunt for the treatment of hypoplastic left heart syndrome (HLHS).
Current Stage: Early
Quantum OPS
Quantum OPS designs devices that facilitate the effortless, rapid, and secure positioning of a patients’ shoulder, arm, hip or knee for surgery.
Current Stage: Growth
Renal Solutions
Renal Solutions sorbent dialysis therapy technology enables flexible patient treatment options by requiring only 6 liters of drinking water to be used. Renal Solutions was acquired by Fresenius Medical Care in November 2007 for a total of $200 million and employs 75+ people locally.
Current Stage: Exited
Rinovum Women’s Health
Rinovum’s product, the Stork™, aids in natural fertility and conception by “supported” natural conception conducted in the privacy of a patient’s home. The market for the product is estimated to be $2.3B World-Wide.
Current Stage: Growth
Rubitection Inc.
Rubitections’ Rubitect Assessment System provides caregivers with a low cost, fast, non-invasive and reliable method to detect and document early-stage pressure ulcers that otherwise would go unnoticed until a more advanced, and expensive, stage.
Current Stage: Seed
Separation Design Group
Separation Design Group’s miniature oxygen generators operate at faster cycle times, resulting in a smaller, lighter, more energy efficient device that can be used in many applications.
Current Stage: Early
Starr Life Sciences
Starr Life Sciences manufactures the MouseOx Plus® pulse oximeter, the world’s first and only patents non-invasive vital signs monitor specifically designed for mice, rats and other small laboratory animals.
Current Stage: Growth
ViaTherm Therapeutics
ViaTherm Therapeutics (previously known as ReGear Life Sciences) offers noninvasive, non-pharmacologic pain management systems based on radio frequency to safely provide deep therapeutic heat to reduce pain.
Current Stage: Growth
Wright Therapy Products
Wright Therapy Products develops and manufactures pneumatic compression devices targeted to the lymphedema, venous insufficiency, physical therapy and sports medicine markets. Wright Therapy Products was acquired by BSN Medical in November 2015.
Current Stage: Exited
Therapeutics
ATRP Solutions
ATRP Solutions capitalized on the process of atom transfer radical polymerization (ATRP)to develop their first large-volume specialty polymer called Advantomer which is targeted to improving the chemistry of fracturing fluids . ATRP Solutions was acquired by Pilot Chemical Company in July 10, 2017.
Current Stage: Growth
Biomed Research & Technologies
Biomed’s product(s) aims to deliver products for the treatment of dermatoses by improving the barrier function of the skin through stimulating of body’s own cells to produce the full complement of skin lipids. Acquired at undisclosed amount.
Current Stage: Exited
Cognition Therapeutics
Cognition Therapeutics (CogRx) is a clinical-stage CNS specialty pharmaceutical company focused on therapeutics which can prevent, stabilize or reverse the course of Alzheimer’s Disease (AD) and related neurodegenerative diseases.
Current Stage: Early
Complexa
Complexa is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of a new class of drugs to treat metabolic and inflammatory disorders through their lead drug candidate, CXA-10 with a focus in several orphan disease conditions characterized by both inflammation and fibrosis.
Current Stage: Early
Diamyd / Nurel
Diamyd Medical develops pharmaceuticals for the treatment of autoimmune diabetes and its complications. Diamyd’s lead product, the diabetes vaccine Diamyd® is current being developed to treat Type 2 and Type 1 diabetes. In November 2005, Diamyd Medical merged with Nurel Therapeutics. The aim is to develop a strong, broader diabetes franchise thereby reducing the risk through diversification and develop efficient therapeutic treatments.
Current Stage: Exited
Knopp Biosciences
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus.
Current Stage: Growth
Lipella Pharmaceuticals
Lipella is a biopharmaceutical company developing drug products and a drug delivery platform for the treatment of diseases and disorders of the bladder. Their disease targets include interstitial cystitis (IC), refractory overactive bladder disorder (OAB) and superficial bladder cancer.
Current Stage: Seed
LSEC
Approximately 43% of women in the U.S. experience some form of sexual dysfunction during their adult lives and more than half of these women have some form of Female Sexual Arousal Disorder (FSAD). LSEC’s product, sold as a single dose target applicator aims to enhances blood flow in the area promoting natural lubrication, arousal and enhancing the overall female sexual experience.
Current Stage: Early
Peptilogics
Peptilogics is a anti-infective company developing novel, first-in-class systemic anti-infective drugs, called Engineered Cationic Antibiotic Peptides (eCAPs), with compelling preclinical proof of concept in treating a broad spectrum of bacterial infections resistant to current antibiotic regimens.
Current Stage: Early
Qrono
Developer of long-acting injectable formulations. The company enables medications, patient adherence, patient outcomes and faster time-to-market using an innovative technology to create long-acting injectable formulations.
Current Stage: Early
Sharp Edge Labs
A preclinical stage therapeutics company developing small molecule drugs for genetic diseases involving protein trafficking.
Current Stage: Seed
Thar Pharmaceuticals
Thar Pharmaceuticals focuses on developing specialty pharmaceutical drugs. The company focuses on transforming intravenous (IV) drugs into oral drugs for existing and new indications. It is developing a pipeline of drug candidates using its proprietary Enhance technology platform. The Company was acquired by The Grünenthal Group (based in Germany) in November 2016 for an undisclosed amount.
Current Stage: Exited
Health IT
Ariel Precision Medicine
ARIEL’s mission is to provide actionable decision support to clinicians for the personalized management of complex chronic disease. The Precision-medicine focused company plans to accomplish this by analyzing a patient’s medical history, genetics and biomarkers with their bioinformatics SMART-MD platform, which creates a personalized diagnosis, prognosis and disease management plan to help clinicians provide precise care.
Current Stage: Seed
Better Body Image
Better Body Image (BBI) offers a mobile application solution that shows what a participant will look like given participant-defined weight loss goal, encouraging participants to stick with their health and wellness program. The application also collects health and wellness data that might complement the EMR and provide individualized medical insights to care providers.
Current Stage: Seed
BlenderHouse
BlenderHouse, a healthcare IT company, aims to solve data entry overload challenges within electronic medical records. BlenderHouse’s product, CompleteNote™, intelligently anticipates data collection and analytic needs of clinical staff during all aspects of patient documentation. This results in more accurate documentation leading to optimized reimbursement and the reduction of costly clinical errors.
Current Stage: Seed
Caliber Infosolutions
Caliber’s lead product, CaliberLIMS®, automates sample management, analytical instruments, test standards, and assay management allowing pharmaceutical and biotech companies to comply with stringent international regulatory requirements such as FDA 21CFR PART 11, Good Laboratory Practices (GLP) and Good Automated Manufacturing Practice (GAMP).
Current Stage: Growth
Dbaza Health
An HIT company that provides a patient onboarding platform with the goal to reduce payer’s costs from chronic disease management, and help patients with multiple chronic conditions (i.e. diabetes) to live better and longer lives.
Current Stage: Growth
DermatologistOnCall
DermatologistOnCall (previously known as Iagnosis) has developed an online care delivery platform with an aim to provide online dermatologists a platform to offer skin care diagnoses and treatment plans to patients. The Company also provides tele-dermatology technology for dermatology providers, practice and health systems.
Current Stage: Growth
Hability
Hability’s platform for Patient Relationship Management (PRM) is currently helping over a dozen outpatient medical providers generate revenue by reducing patient self-discharge, encouraging positive reviews and patient referrals, and cultivating lifelong, loyal customers.
Current Stage: Growth
Health Monitoring Systems
Health Monitoring Systems (HMS) aggregates an automates healthcare data from over 500 U.S. hospital systems in order to monitor and identify disease outbreak and bioterrorism events quickly. HMS’ novel, weather map like design is the largest private repository of these data. The U.S. public health surveillance market is approximately $500 Million.
Current Stage: Growth
Medrespond
Medrespond’s online platform, powered with a patented ‘answer-to-queries’ technology called Synthetic Interviews™, integrates artificial intelligence, search and streaming media to meet both healthcare enterprises and patient’s requirements for healthcare communications in wellness coaching, disease management and discharge support. .
Current Stage: Growth
MedSage Technologies
Since its founding in 2003, MedSage has focused on one goal, to be a provider of patient-management software designed to help home medical equipment (HME) providers improve compliance and outcomes, and streamline the re-supply process for patients with OSA, diabetes and other diseases. The Company was acquired by Philips Respironics in January 2011.
Current Stage: Exited
Mental Health Metrics, LLC
A population-health management company that utilizes statistical process management techniques to intervene in patient care before adverse events occur.
Current Stage: Seed
PeriOptimum
PeriOptimum develops and sells state-of-the art industrial design-based workflow management tools to maximize capacity and optimize surgical operating room (OR) utilization rates, by utilizing RFID technology. The Company was acquired by Steris Corporation in October 2010 for an undisclosed amount.
Current Stage: Exited
PHRQL
Personal Health Recording for Quality of Life (PHRQL) has created an enterprise-level electronic health record (EHR) system for medical nutrition therapy that enables registered dieticians in retail grocery settings or independent practices to help customers develop healthy eating plans for general health and wellness.
Current Stage: Seed
Treatspace
Treatspace has developed a technology that connects healthcare providers to simplify referral workflows, ensuring patients get appointments and that consult reports are returned.
Current Stage: Growth
Wellbridge Health
Wellbridge Health is a Pittsburgh-based Digital Health company that offers an innovative care management program designed to address the complex medical and socio-economic needs of high-risk Medicaid and Medicare Advantage beneficiaries.
Current Stage: Early
Diagnostics
Advanced Technology Healthcare Solutions
Advanced Technology Healthcare Solutions, a bioinformatics company is committed to implementing advanced technologies to improve the quality of patient care while helping to reduce healthcare costs. The Company is developing a personalized, genomic medicine initiative targeting the pediatric population and to help provide parents and pediatricians with better decision-making tools. The Company merged with Brainstage.
Current Stage: Seed
Cellatope
Cellatope Corporation, a cell analysis company, develops research and diagnostic products and services for autoimmune diseases. It offers cell-bound complement activation products for the diagnosis and monitoring of systemic lupus erythematosus.
Current Stage: Exited
Cernostics
Cernostics, a molecular diagnostics company, is aiming to deliver the next generation technologies to help in better cancer prognosis and diagnosis by creating advanced cancer diagnostic tests based on their proprietary integrated digital pathology platform, Tissue Systems Pathology™ (TSP). Their product, TissueCypher® is first-of-its kind diagnostic test to be used to predict the risk of developing esophageal cancer in patients with Barrett’s esophagus.
Current Stage: Growth
NanoLambda
NanoLambda is developing Apollo™, a non-invasive diagnostic platform for a broad range of light, color and material sensing applications such as; bio-chemical detection, wearable health monitoring and environment monitoring. Unlike expensive and bulky conventional solutions, NanoLambda’s technology is ultra-compact and affordable for broader consumer healthcare and environmental safety applications.
Current Stage: Early
RedPath Integrated Pathology
RedPath’s patented PathFinderTG™ technology enables an early and definitive diagnosis for difficult cases where cancer is suspected or pre-cancerous conditions exist. The company’s initial product aim was pancreatic cancer and follow-on products included Barrett’s Esophagus, Glioma and Liver Cancer. The Company was acquired by PDI in November 2014 for an undisclosed amount.
Current Stage: Exited
Biotech Tools
Applied Isotope Technologies
Applied Isotope Technologies, Inc. (AIT) is a commercial-stage analytics company selling products and services for highly accurate, subtrace-level, speciated analysis using Direct Speciated Isotope Dilution Mass Spectrometry (D-SIDMS).
Current Stage: Growth
Cellumen
Cellumen is the leading innovator in cellular systems biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. The Company was acquired by Apredica on August 2010.
Current Stage: Exited
Celsense
Celsense, a privately-held biotechnology company, has developed perfluorocarbon technology to allow the visualization of cellular therapies non-invasively using fluorine magnetic resonance imaging (fMRI). Their novel imaging agents are offered in two product families; Cell Sense (used to image administration, migration and persistence of transplanted cells) and V-Sense (used to image localized inflammation).
Current Stage: Growth
Crystalplex
Crystalplex, a nanotechnology company provides the world’s first and only alloy gradient SapphireTM Quantum Dots (QDs) for application in the optoelectronics industry.
Current Stage: Growth
ICx Agentase
Agentase develops and implements biocatalysts used in such applications as pesticide remediation, water treatments, wound healing ointments, biosensors, and detoxification of nerve agents. Agentase was acquired by ICx which was later acquired by FLIR systems in August 2010.
Current Stage: Exited
Immunetrics
Immunetrics, a bio simulation company, offers a suite of comprehensive computer modeling products to simulate human and animal response to the activation or attenuation of pathological cellular signaling pathways. Immunetrics’ powerful modeling technology allows researchers and clinicians to make well-informed decisions about outcomes based on a defined set of inputs.
Current Stage: Growth
MS2 Array, LLC
MS2 Array has developed a proprietary, epigenetics assay by bringing together the best of high-throughput mass spectrometry (HT-MS) technology and microarrays with the aim to elevate the high-throughput technology from data accumulation to small molecule drug discovery and development.
Current Stage: Seed
SpectraGenetics
SpectraGenetics provides innovative gene tagging technologies to accurately determine when a gene is expressed, and to visualize in real-time the expression, cellular localization or activation of proteins in living cells. These tagging technologies will be used in drug discovery and development.
Current Stage: Growth